Plexium focuses on targeted protein degraders to reinvent the way medicines are discovered.

The company's DELPhe platform, named for DNA-Encoded Library (DEL) phenotypic (Phe) screening, is a unique drug discovery engine designed to identify novel small molecules for multiple indications, including cancer and inflammatory disease indications.

• Industry

  • Biotechnology
  • Health + Tech

• Milestones

  • Lux investment: 2021

• Founders

  • Swamy Vijayan, PhD

  LUX Partners

  • Adam Goulburn

• Latest Tweets

  • #Plexium is looking to expand our team of drug hunters, with openings for positions such as Principal Scientist and… https://t.co/qDzlegrZss@PlexiumTx - 06:08 PM Apr 26th
  • Our approach to TPD is highlighted in poster #1283 at this year's AACR meeting. We describe the discovery & unique… https://t.co/spM3wtUf7i@PlexiumTx - 05:11 PM Apr 19th
  • Big news today – we closed a $35M financing w/ @Lux_Capital, Pivotal Bioventures, The Column Group, @DCVC and other… https://t.co/jtR1hty52Z@PlexiumTx - 01:19 PM Jan 21st